Clinical Trial Update: Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating crizanlizumab alone or with nivolumab for glioblastoma and melanoma brain metastases is currently recruiting at Sheba Medical Center.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Melanoma Brain Metastases

Drugs mentioned

• ADAKVEO (crizanlizumab)
• OPDIVO (nivolumab)

Snippet

Sponsor: Sheba Medical Center | Conditions: Advanced Glioblastoma, Metastatic Melanoma in the Central Nervous System | Phase 2 | Status: RECRUITING